<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="int-interactant" /><meta name="keywords" content="" /><title>Saquinavir: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="41001i791.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="41001i791.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=41001i791.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="41001.htm">Appendix 1 Interactions</a> &gt; <a href="53178.htm">List of drug interactions</a> &gt; <a href="41001i391.htm">Antivirals</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="41001i400.htm" title="Previous: Ritonavir">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="41001i401.htm" title="Next: Stavudine">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1 id="_41001i791">Saquinavir</h1><div id="pC" class="jN"><p class="int-specific-drug-name"><b>Saquinavir</b>
          has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody><tr><td><a href="41001i86.htm">Alfentanil</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  saquinavir given with alfentanil—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i118.htm">Amiodarone</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  saquinavir given with amiodarone—avoid concomitant use</b></td><td>Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped</td></tr><tr><td><a href="41001i241.htm">Antidepressants, Tricyclic</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  saquinavir given with tricyclics—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i293.htm">Antifungals, Imidazole</a></td><td>plasma concentration of  saquinavir possibly increased by imidazoles </td><td></td></tr><tr><td><a href="41001i300.htm">Antifungals, Triazole</a></td><td>plasma concentration of  saquinavir possibly increased by triazoles </td><td></td></tr><tr><td><a href="41001i1217.htm" name="_1217">Apixaban</a></td><td>avoidance of  saquinavir advised by manufacturer of apixaban </td><td></td></tr><tr><td><a href="41001i1011.htm" name="_1011">Aripiprazole</a></td><td class="cBV"><b> saquinavir possibly inhibits metabolism of aripiprazole (reduce dose of aripiprazole)</b></td><td></td></tr><tr><td><a href="41001i937.htm" name="_937">Artemether with Lumefantrine</a></td><td>caution with  saquinavir advised by manufacturer of artemether/lumefantrine </td><td></td></tr><tr><td><a href="41001i1005.htm">Atazanavir</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  saquinavir given with atazanavir—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i601.htm" name="_601">Atorvastatin</a></td><td>possible increased risk of myopathy when  saquinavir given with atorvastatin </td><td></td></tr><tr><td><a href="41001i1204.htm" name="_1204">Cabazitaxel</a></td><td class="cBV"><b>avoidance of  saquinavir advised by manufacturer of cabazitaxel </b></td><td></td></tr><tr><td><a href="41001i277.htm">Carbamazepine</a></td><td>plasma concentration of  saquinavir possibly reduced by carbamazepine </td><td></td></tr><tr><td><a href="41001i499.htm">Ciclosporin</a></td><td class="cBV"><b>plasma concentration of both drugs increased when  saquinavir given with ciclosporin </b></td><td></td></tr><tr><td><a href="41001i744.htm">Cimetidine</a></td><td>plasma concentration of  saquinavir possibly increased by cimetidine </td><td></td></tr><tr><td><a href="41001i168.htm">Clarithromycin</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  saquinavir given with clarithromycin—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i364.htm">Clozapine</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  saquinavir given with clozapine—avoid concomitant use</b></td><td>Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis</td></tr><tr><td><a href="41001i161.htm">Dapsone</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  saquinavir given with dapsone—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1076.htm" name="_1076">Darifenacin</a></td><td>avoidance of  saquinavir advised by manufacturer of darifenacin </td><td></td></tr><tr><td><a href="41001i1091.htm" name="_1091">Darunavir</a></td><td> saquinavir reduces plasma concentration of darunavir </td><td></td></tr><tr><td><a href="41001i490.htm">Dexamethasone</a></td><td>plasma concentration of  saquinavir possibly reduced by dexamethasone </td><td></td></tr><tr><td><a href="41001i119.htm">Disopyramide</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  saquinavir given with disopyramide—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1176.htm">Dronedarone</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  saquinavir given with dronedarone—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i874.htm">Efavirenz</a></td><td>plasma concentration of  saquinavir significantly reduced by efavirenz </td><td></td></tr><tr><td><a href="41001i1025.htm" name="_1025">Eplerenone</a></td><td> saquinavir increases plasma concentration of eplerenone (reduce dose of eplerenone)</td><td></td></tr><tr><td><a href="41001i563.htm" name="_563">Ergotamine and Methysergide</a></td><td class="cBV"><b>increased risk of ergotism when  saquinavir given with ergotamine and methysergide—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i169.htm">Erythromycin</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  saquinavir given with erythromycin—avoid concomitant use</b></td><td>Interactions do not apply to small amounts of erythromycin used topically</td></tr><tr><td><a href="41001i914.htm">Esomeprazole</a></td><td class="cBV"><b>plasma concentration of  saquinavir possibly increased by esomeprazole—manufacturer of saquinavir advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1169.htm" name="_1169">Everolimus</a></td><td class="cBV"><b> saquinavir possibly increases plasma concentration of everolimus—manufacturer of everolimus advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i95.htm">Fentanyl</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  saquinavir given with fentanyl—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1119.htm" name="_1119">Fesoterodine</a></td><td>manufacturer of fesoterodine advises dose reduction when  saquinavir given with fesoterodine—consult fesoterodine product literature</td><td></td></tr><tr><td><a href="41001i120.htm">Flecainide</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  saquinavir given with flecainide—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i387.htm">Haloperidol</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  saquinavir given with haloperidol—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i398.htm">Indinavir</a></td><td>plasma concentration of  saquinavir increased by indinavir </td><td></td></tr><tr><td><a href="41001i298.htm">Ketoconazole</a></td><td>plasma concentration of  saquinavir increased by ketoconazole </td><td></td></tr><tr><td><a href="41001i753.htm">Lansoprazole</a></td><td class="cBV"><b>plasma concentration of  saquinavir possibly increased by lansoprazole—manufacturer of saquinavir advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1128.htm" name="_1128">Lapatinib</a></td><td class="cBV"><b>avoidance of  saquinavir advised by manufacturer of lapatinib </b></td><td></td></tr><tr><td><a href="41001i55.htm">Lidocaine</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  saquinavir given with lidocaine—avoid concomitant use</b></td><td>Interactions less likely when lidocaine used topically</td></tr><tr><td><a href="41001i922.htm" name="_922">Lopinavir</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  saquinavir given with lopinavir—avoid concomitant use</b></td><td>In combination with ritonavir as <i>Kaletra</i>® (ritonavir is present to inhibit lopinavir metabolism and increase plasma-lopinavir concentration)—see also Ritonavir</td></tr><tr><td><a href="41001i1107.htm" name="_1107">Maraviroc</a></td><td class="cBV"><b> saquinavir increases plasma concentration of maraviroc (consider reducing dose of maraviroc)</b></td><td></td></tr><tr><td><a href="41001i97.htm">Methadone</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  saquinavir given with methadone—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i421.htm">Midazolam</a></td><td class="cBV"><b> saquinavir increases plasma concentration of midazolam (risk of prolonged sedation—avoid concomitant use of <i>oral</i> midazolam)</b></td><td></td></tr><tr><td><a href="41001i841.htm">Mizolastine</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  saquinavir given with mizolastine—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i842.htm">Nelfinavir</a></td><td class="cBV"><b>plasma concentration of  saquinavir increased by nelfinavir—manufacturer of saquinavir advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i752.htm">Omeprazole</a></td><td class="cBV"><b>plasma concentration of  saquinavir increased by omeprazole—manufacturer of saquinavir advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i754.htm">Pantoprazole</a></td><td class="cBV"><b>plasma concentration of  saquinavir possibly increased by pantoprazole—manufacturer of saquinavir advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1186.htm" name="_1186">Pazopanib</a></td><td class="cBV"><b>avoidance of  saquinavir advised by manufacturer of pazopanib </b></td><td></td></tr><tr><td><a href="41001i808.htm">Pentamidine Isetionate</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  saquinavir given with pentamidine isetionate—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i437.htm">Phenobarbital</a></td><td class="cBV"><b>plasma concentration of  saquinavir possibly reduced by phenobarbital </b></td><td></td></tr><tr><td><a href="41001i373.htm">Phenothiazines</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  saquinavir given with phenothiazines—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td>plasma concentration of  saquinavir possibly reduced by phenytoin </td><td></td></tr><tr><td><a href="41001i369.htm" name="_369">Pimozide</a></td><td class="cBV"><b> saquinavir possibly increases plasma concentration of pimozide (increased risk of ventricular arrhythmias—avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i125.htm">Propafenone</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  saquinavir given with propafenone—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i824.htm" name="_824">Quetiapine</a></td><td class="cBV"><b> saquinavir possibly increases plasma concentration of quetiapine—manufacturer of quetiapine advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i341.htm">Quinine</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  saquinavir given with quinine—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i869.htm">Rabeprazole</a></td><td class="cBV"><b>plasma concentration of  saquinavir possibly increased by rabeprazole—manufacturer of saquinavir advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1147.htm" name="_1147">Ranolazine</a></td><td class="cBV"><b> saquinavir possibly increases plasma concentration of ranolazine—manufacturer of ranolazine advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i200.htm" name="_200">Rifabutin</a></td><td class="cBV"><b> saquinavir increases plasma concentration of rifabutin (also plasma concentration of saquinavir reduced)</b></td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td class="cBV"><b>plasma concentration of  saquinavir significantly reduced by rifampicin , also risk of hepatotoxicity—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td class="cBV"><b>plasma concentration of  saquinavir increased by ritonavir </b></td><td></td></tr><tr><td><a href="41001i1136.htm" name="_1136">Rivaroxaban</a></td><td>avoidance of  saquinavir advised by manufacturer of rivaroxaban </td><td></td></tr><tr><td><a href="41001i974.htm" name="_974">Rosuvastatin</a></td><td class="cBV"><b>possible increased risk of myopathy when  saquinavir given with rosuvastatin—manufacturer of rosuvastatin advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i858.htm">Sildenafil</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  saquinavir given with sildenafil—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i605.htm">Simvastatin</a></td><td class="cBV"><b>increased risk of myopathy when  saquinavir given with simvastatin (avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i455.htm">Sotalol</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  saquinavir given with sotalol—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i905.htm">St John's Wort</a></td><td class="cBV"><b>plasma concentration of  saquinavir reduced by St John's wort—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i730.htm" name="_730">Tacrolimus</a></td><td class="cBV"><b> saquinavir increases plasma concentration of tacrolimus (consider reducing dose of tacrolimus)</b></td><td>Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="119635.htm#_119635">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</td></tr><tr><td><a href="41001i945.htm">Tadalafil</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  saquinavir given with tadalafil—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i946.htm" name="_946">Telithromycin</a></td><td class="cBV"><b>avoidance of concomitant  saquinavir in severe renal and hepatic impairment advised by manufacturer of telithromycin </b></td><td></td></tr><tr><td><a href="41001i1055.htm">Tipranavir</a></td><td class="cBV"><b>plasma concentration of  saquinavir reduced by tipranavir </b></td><td></td></tr><tr><td><a href="41001i850.htm" name="_850">Tolterodine</a></td><td>avoidance of  saquinavir advised by manufacturer of tolterodine </td><td></td></tr><tr><td><a href="41001i255.htm">Trazodone</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  saquinavir given with trazodone—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i967.htm">Vardenafil</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  saquinavir given with vardenafil—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i222.htm" name="_222">Warfarin</a></td><td> saquinavir possibly enhances anticoagulant effect of warfarin </td><td></td></tr></tbody></table><p>Saquinavir belongs to <b>Antivirals</b>
          but <b>Antivirals</b>
          has no interactions information.
        </p></div><?highlighter on?><?highlighter off?><div id="pE">◄ <a accesskey="[" href="41001i400.htm">Previous: Ritonavir</a> | <a class="top" href="41001i791.htm#">Top</a> | <a accesskey="]" href="41001i401.htm">Next: Stavudine</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>